Zhongshan Belling Biotechnology Co., Ltd.
As of 18 November 2026, for the company name Zhongshan Belling Biotechnology Co., Ltd. as recorded, 3 active API registrations list this name as first registered company.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.
Drug filings
4 acceptance records as first applicant, grouped into 4 source drug names. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Upadacitinib Sustained-release Tablets 1 records · Latest accepted 2026/11/02
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2602676 | Generic | 2026/11/02 | Zhongshan Belling Biotechnology Co., Ltd.; Guangzhou Green Cross Pharmaceutical Co.,Ltd. | CDE ↗ |
Minoxidil Liniment 1 records · Latest accepted 2026/07/28
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2601811 | Generic | 2026/07/28 | Zhongshan Belling Biotechnology Co., Ltd.; Zhongshan Wanhan Pharmaceuticals Co., Ltd. | CDE ↗ |
Iron Proteinsuccinylate Oral Solution 1 records · Latest accepted 2025/03/25
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2501167 | Generic | 2025/03/25 | Zhongshan Belling Biotechnology Co., Ltd.; Hua Yi Tai Kang Pharma Co., Ltd. romanized | CDE ↗ |
Ursodeoxycholic Acid Tablets 1 records · Latest accepted 2024/12/18
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404398 | Generic | 2024/12/18 | Zhongshan Belling Biotechnology Co., Ltd.; An Shi Pharmaceutical (Zhong Shan) Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
1 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Accepted: 1 application
- 2026/11/02Accepted
Upadacitinib Sustained-release Tablets
CYHS2602676
Fact date: 2026/11/02 · Date added to this site: 2026/11/03
View source ↗
Under review
4 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Upadacitinib Sustained-release Tablets | CYHS2602676 | Generic | 2026/11/02 | Zhongshan Belling Biotechnology Co., Ltd.; Guangzhou Green Cross Pharmaceutical Co.,Ltd. | CDE ↗ |
| Minoxidil Liniment | CYHS2601811 | Generic | 2026/07/28 | Zhongshan Belling Biotechnology Co., Ltd.; Zhongshan Wanhan Pharmaceuticals Co., Ltd. | CDE ↗ |
| Iron Proteinsuccinylate Oral Solution | CYHS2501167 | Generic | 2025/03/25 | Zhongshan Belling Biotechnology Co., Ltd.; Hua Yi Tai Kang Pharma Co., Ltd. romanized | CDE ↗ |
| Ursodeoxycholic Acid Tablets | CYHS2404398 | Generic | 2024/12/18 | Zhongshan Belling Biotechnology Co., Ltd.; An Shi Pharmaceutical (Zhong Shan) Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
0 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
3 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 熊去氧胆酸 · No verified English name | Zhongshan Belling Biotechnology Co., Ltd. | Y20240000171 | A | 2026/05/20 | CDE ↗ |
| 牛磺熊去氧胆酸 · No verified English name | Zhongshan Belling Biotechnology Co., Ltd. | Y20230000982 | A | 2025/10/14 | CDE ↗ |
| 熊去氧胆酸 · No verified English name | Zhongshan Belling Biotechnology Co., Ltd. | Y20190009907 | A | 2024/07/09 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.
This source was last successfully updated at 2026/11/18; current coverage may be incomplete.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/18 · Current coverage may be incomplete
- Chemical-drug catalogue
- Last successful update: 2026/11/18
- API registrations
- Last successful update: 2026/11/18
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.